10/29/2025
MEDICAL CASE REPORT:
Use of Ivermectin and Mebendazole in a 44-Year-Old Male with Glioblastoma Multiforme (Jakarta, Indonesia)
Case Summary:
A 44-year-old male from Jakarta, Indonesia, diagnosed with Glioblastoma Multiforme (GBM) in mid-2024, presented to our online telehealth program in February 2025. The patient had previously undergone standard-of-care radiation therapy and temozolomide-based chemotherapy, which were completed in October 2024. Post-treatment imaging revealed limited improvement, and he was informed by his oncology team that no further therapeutic options were likely to yield significant benefit.
The patient reached out to our telehealth program after reading several testimonials online. He expressed initial skepticism regarding antiparasitic drug repurposing but was willing to pursue an integrative approach after thorough consultation and review of available clinical data.
Treatment Protocol:
• Iver&&&ctin: &&mg/kg/day (oral administration)
• Meb****azole: &&&&mg/day (divided doses)
Both agents were administered under careful supervision via telemonitoring. Supportive nutritional and detoxification measures were also recommended.
Clinical Progress:
After approximately six months of therapy (February–August 2025), repeat MRI brain imaging demonstrated a reduction in tumor volume, with partial resolution of peritumoral edema and improved neurological symptoms.
The patient reported increased energy, improved coordination, and a significant reduction in headaches and cognitive fog. Laboratory parameters, including liver and renal function tests, remained within normal limits throughout treatment.
Discussion:
The patient’s oncology team expressed surprise at the radiologic improvement, attributing the findings to delayed effects of prior radiation and chemotherapy completed nearly a year earlier. However, the timing of the tumor response closely aligned with the initiation of the Ivermectin and Mebendazole regimen.
Although anecdotal, such responses warrant further investigation into the potential synergistic or standalone effects of these antiparasitic agents in neuro-oncology.
Conclusion:
This case contributes to a growing body of observational evidence suggesting a possible therapeutic role for Ivermectin and Mebendazole in glioblastoma management, particularly in refractory cases.
Note: This report is based on real patient feedback received through our online telehealth program. Further controlled clinical studies are needed to validate these outcomes.
Disclaimer:
This case report is intended for educational and informational purposes only and does not constitute medical advice. Patients should consult with qualified healthcare professionals before initiating any treatment. William Makis MD
